21,611 reports of this reaction
7.2% of all Xarelto reports
#1 most reported adverse reaction
GASTROINTESTINAL HAEMORRHAGE is the #1 most commonly reported adverse reaction for Xarelto, manufactured by Janssen Pharmaceuticals, Inc.. There are 21,611 FDA adverse event reports linking Xarelto to GASTROINTESTINAL HAEMORRHAGE. This represents approximately 7.2% of all 302,183 adverse event reports for this drug.
Patients taking Xarelto who experience gastrointestinal haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROINTESTINAL HAEMORRHAGE is moderately reported among Xarelto users, representing a notable but not dominant share of adverse events.
In addition to gastrointestinal haemorrhage, the following adverse reactions have been reported for Xarelto:
The following drugs have also been linked to gastrointestinal haemorrhage in FDA adverse event reports:
GASTROINTESTINAL HAEMORRHAGE has been reported as an adverse event in 21,611 FDA reports for Xarelto. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROINTESTINAL HAEMORRHAGE accounts for approximately 7.2% of all adverse event reports for Xarelto, making it one of the most commonly reported side effect.
If you experience gastrointestinal haemorrhage while taking Xarelto, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.